BACKGROUND: @entity1667 is the only neuroprotective therapy advocated in acute non-penetrating @entity1566 . Trials indicate improved neurological outcome following early administration of a high dose regime. The National Spinal Injuries Unit (NSIU) has promoted this regime by a simple laminated poster sent to all Irish A_E departments. AIM: To assess the use of @entity1667 in @entity1 with @entity1566 . METHODS: A retrospective audit of @entity1 data for all @entity1 admitted with traumatic @entity16 over a 12-month period. RESULTS: One hundred ninety-six @entity1 were admitted during the study period, 28 (14%) received intravenous @entity1667 of which six had clear records documenting compliance. One @entity1 received both @entity619 and @entity1667 in high doses and three had incorrect bolus dosages administered. Six @entity1 received @entity1667 infusion longer than the protocol, while five @entity1 were given infusions shorter than recommended. Three @entity1 were admitted to the unit that could have received the @entity134 regime at the point of transfer. CONCLUSIONS: There was poor documentation of prescription orders and timing of administration. Only six @entity1 had clear documentation allowing confirmation of adherence to the protocol of the National Acute @entity1566 Study (NASCIS) III trial.

@entity1667 in acute XXXX .

@entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone', 'Methylprednisolone'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological impairment'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injuries', 'Spinal Cord Injury', 'spinal cord injury']
@entity1566 :: (MESH:D013119,Disease) :: ['spinal cord injuries']
